Will Cascadian Therapeutics Inc (USA) (CASC) Go Down Anytime Soon?

September 17, 2017 - By Maria Brooks

The stock of Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) is a huge mover today! The stock increased 4.09% or $0.15 on September 15, reaching $3.82. About 847,604 shares traded or 164.62% up from the average. Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) has declined 30.85% since September 17, 2016 and is downtrending. It has underperformed by 47.55% the S&P500.
The move comes after 9 months positive chart setup for the $193.11 million company. It was reported on Sep, 17 by Barchart.com. We have $4.13 PT which if reached, will make NASDAQ:CASC worth $15.45 million more.

Wall Street await Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) to release earnings on November, 6. Analysts forecast earnings per share of $-0.28, up exactly $0.26 or 48.15 % from 2014’s $-0.54 EPS. After posting $-0.30 EPS for the previous quarter, Cascadian Therapeutics Inc (USA)’s analysts now forecast -6.67 % EPS growth.

More notable recent Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) news were published by: Seekingalpha.com which released: “Cascadian Therapeutics: Worth Much More Than The Present Share Price” on March 23, 2017, also Seekingalpha.com with their article: “Cascadian Therapeutics’ (CASC) CEO Scott Myers On Q2 2017 Results – Earnings …” published on August 09, 2017, Globenewswire.com published: “Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President …” on January 04, 2017. More interesting news about Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) were released by: Globenewswire.com and their article: “Cascadian Therapeutics to Report Second Quarter 2017 Financial Results on …” published on August 01, 2017 as well as Globenewswire.com‘s news article titled: “Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress” with publication date: January 05, 2017.

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The company has market cap of $193.11 million. The Firm focuses on the development of therapeutic products for the treatment of cancer. It currently has negative earnings. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor 2 inhibitor.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: